NovAccess Global, Inc. CEO Interviewed On MoneyTV

Rhea-AI Summary

NovAccess Global (OTC PINK:XSNX) announced that Dr. Dwain Irvin was interviewed on MoneyTV on September 11, 2021. MoneyTV, celebrating its 25th year, reaches 200 million homes across 75 countries. Dr. Irvin discussed the company's efforts to gain FDA approval for a Phase IIa Human clinical trial of an immunotherapy targeting brain tumors. NovAccess is advancing a cancer vaccine aimed at enhancing immune responses for patients with glioblastoma multiforme, a serious brain tumor with a limited survival rate.

Positive

• Interview on MoneyTV provides exposure to investors and the public.
• Company's immunotherapy targets glioblastoma multiforme, addressing a significant medical need.
• Development of a cancer vaccine may improve patient outcomes and quality of life.

Negative

• None.

CLEVELAND, OH / ACCESSWIRE / September 15, 2021 / NovAccess Global, Inc. (OTC PINK:XSNX) announced Dr. Dwain Irvin's interview on MoneyTV aired on September 11, 2021.

MoneyTV has been in the business for 25 years, reaching 200 million homes in 75 countries. Dr. Dwain Irvin's interview can be watched here.

https://novaccessglobal.com/

Dr. Dwain Irvin was interviewed by Don Baillargeon, a broadcast industry veteran of more than 30 years. Don Baillargeon is the Founder, Executive Producer, and Anchor of MoneyTV, an internationally syndicated weekly business television program reaching more than 200 million TV households globally. MoneyTV debuted in 1996, recently began its 25th year on television, and produced and broadcasted its 1,100th original episodes.

Dr. Irvin provides insight into the company's pursuits to obtain FDA approval to initiate a Phase IIa Human clinical trial with their novel immunotherapy against brain tumors.

About NovAccess Global
NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.

NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our company has a novel immunotherapeutic approach to treat brain tumor patients with glioblastoma multiforme, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of Toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. The company owns a cancer vaccine, which is a medication that stimulates or restores the immune system's ability to fight existing cancer by strengthening the body's natural defenses against the cancer cells. It is a meaningful technology which could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit novaccessglobal.com.

Forward-Looking Statement
This press release and its attachments contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude or risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the company's disclosures or filings with the Securities Exchange Commission and/or OTC Markets, Inc. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess, Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.

Investor Relations Contact:
Satya Chillara
Darrow Associates
(510) 396 -2776
schillara@darrowassociates.com

SOURCE: NovAccess Global Inc.

View source version on accesswire.com:
https://www.accesswire.com/664166/NovAccess-Global-Inc-CEO-Interviewed-On-MoneyTV

FAQ

What did Dr. Dwain Irvin discuss in his MoneyTV interview on September 11, 2021?

Dr. Dwain Irvin discussed NovAccess Global's pursuit of FDA approval for a Phase IIa Human clinical trial of its immunotherapy for brain tumors.

What is the focus of NovAccess Global's cancer vaccine therapy?

The company is developing a cancer vaccine therapy aimed at enhancing the immune response in patients with glioblastoma multiforme.

What is the significance of glioblastoma multiforme in cancer treatment?

Glioblastoma multiforme is the most common adult brain tumor, known for its poor prognosis and limited survival rates after diagnosis.

How many households does MoneyTV reach?

MoneyTV reaches 200 million homes across 75 countries.

What is the stock symbol for NovAccess Global?

The stock symbol for NovAccess Global is XSNX.